ReviewF1000Research2015
Progressive Multifocal Leukoencephalopathy.
Review in F1000Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 93 citations in OpenAlex.
- Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting.Inflammatory bowel diseases · 2018Trial
- Immune Evasion by Neurotropic Viruses: Molecular Strategies, Cellular Targets, and Consequences for CNS Infection.International journal of molecular sciences · 2026Review
- Intraoperative contrast-enhanced ultrasound features of progressive multifocal leukoencephalopathy: a case report.Frontiers in neuroimaging · 2026Article
- Ethical and Clinical Considerations in the Workup of HIV-Associated Neurocognitive Decline.Cureus · 2025Article
- A study on the distribution of BK and JC polyomavirus in discarded donor kidneys.Frontiers in transplantation · 2025Article
- Article
- Longitudinal study of human polyomaviruses viruria in kidney transplant recipients.Clinical and experimental medicine · 2024Article
- Progressive Multifocal Leukoencephalopathy Associated With Idiopathic CD8+ Lymphocytopenia.Cureus · 2022Article
- Article
- Complexities of JC Polyomavirus Receptor-Dependent and -Independent Mechanisms of Infection.Viruses · 2022Review
- Biogenesis of JC polyomavirus associated extracellular vesicles.Journal of extracellular biology · 2022Article
- Approach to an Intracranial Mass in Patients With HIV.Current neurology and neuroscience reports · 2020Review
- Infections in the Era of Targeted Therapies: Mapping the Road Ahead.Frontiers in medicine · 2020Article
- The Progressive Multifocal Leukoencephalopathy Consortium as a Model for Advancing Research and Dialogue on Rare Severe Adverse Drug Reactions.Advances in therapy · 2019Article
- Progressive Multifocal Leukoencephalopathy: Current Insights.Degenerative neurological and neuromuscular disease · 2019Review
- Not All Strokes Are Strokes An Example of Diagnostic Confirmation Bias.European journal of case reports in internal medicine · 2019Article
- What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?Inflammatory bowel diseases · 2018Article
- Detection and analysis of variants of JC polyomavirus in urine samples from HIV-1-infected patients in China's Zhejiang Province.The Journal of international medical research · 2018Article
- Reducing persistent polyomavirus infection increases functionality of virus-specific memory CD8 T cells.Virology · 2017Article
- Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.Current infectious disease reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease with significant morbidity and mortality and no effective, targeted therapies. It is most often observed in association with abnormalities of cell-mediated immunity, in particular human immunodeficiency virus (HIV) infection, but also occurs in association with lymphoproliferative diseases, certain immunosuppressive and immunomodulatory regimens, and other conditions. The etiologic agent of PML is a small, ubiquitous polyomavirus, the JC virus (JCV, also known as JCPyV), for which at least 50% of the adult general population is seropositive. PML results when JCV replicates within cerebral oligodendrocytes and astrocytes, leading to oligodendrocyte death and demyelination. Unfortunately, no treatments have been convincingly demonstrated to be effective, though some have been employed in desperation; treatment otherwise includes attempts to restore any immune system defect, such as the withdrawal of the causative agent if possible, and general supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.